{"version":"1.0","provider_name":"IFPMA","provider_url":"https:\/\/www.ifpma.org","title":"IFPMA remarks on intellectual property management and the global response to COVID-19 | IFPMA","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"kn9791PmM6\"><a href=\"https:\/\/www.ifpma.org\/news\/ifpma-remarks-on-intellectual-property-management-and-the-global-response-to-covid-19\/\">IFPMA remarks on intellectual property management and the global response to COVID-19<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.ifpma.org\/news\/ifpma-remarks-on-intellectual-property-management-and-the-global-response-to-covid-19\/embed\/#?secret=kn9791PmM6\" width=\"600\" height=\"338\" title=\"&#8220;IFPMA remarks on intellectual property management and the global response to COVID-19&#8221; &#8212; IFPMA\" data-secret=\"kn9791PmM6\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"\u00a0In the fight against the novel coronavirus (COVID-19), biopharmaceuticals companies are focusing significant amounts of their resources on the immediate task ahead, which requires pushing the boundaries of science, developing workable solutions and ensuring there is capacity to scale up manufacture once solutions are found, while at the same time ensuring continuity of global supply for critical products. This approach is bearing fruit, with a large number of competitive leads for treatments and vaccines already identified for testing in just a matter of a couple of months.","thumbnail_url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-social-preview.png","thumbnail_width":801,"thumbnail_height":801}